共 542 条
[1]
Ghosh N(2015)Expanding role of lenalidomide in hematologic malignancies Cancer Manag Res 7 105-119
[2]
Grunwald MR(2012)Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide Leukemia 26 2326-2335
[3]
Fasan O(2011)Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide Blood 118 4771-4779
[4]
Bhutani M(2014)Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 (CRBN) Br J Haematol 164 811-821
[5]
Lopez-Girona A(2013)Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma Leuk Lymphoma 54 683-687
[6]
Mendy D(2011)Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary cns tumors: pediatric brain tumor consortium study PBTC-018 J Clin Oncol 29 324-329
[7]
Ito T(2011)Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a children’s oncology group phase I consortium report J Clin Oncol 29 316-323
[8]
Miller K(2009)A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme Int J Radiat Oncol Biol Phys 73 222-227
[9]
Gandhi AK(2007)A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors Am Assoc Cancer Res 13 7101-7106
[10]
Kang J(2006)Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study J Clin Oncol 24 5343-5349